Most patients with NSCLC harboring sensitizing epidermal growth factor receptor (EGFR) mutations confer a high response rate of 70%–80% to EGFR‐tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.3, 4, 5. This evidence concerns the gene EGFR and non-small cell lung carcinoma.